1h Free Analyst Time
Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
The Publisher's Medical Devices sector report, “Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019" provides an overview of Retrovirus Rapid Tests & Point of Care (POC) currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Retrovirus Rapid Tests & Point of Care (POC) pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by the Publisher's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Retrovirus Rapid Tests & Point of Care (POC) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Retrovirus Rapid Tests & Point of Care (POC) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to:
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Retrovirus Rapid Tests & Point of Care (POC) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
1.1 List of Tables1.2 List of Figures
2 Introduction
3 Products under Development
4 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products under Development by Companies
5 Retrovirus Rapid Tests & Point of Care (POC) Companies and Product Overview
6 Retrovirus Rapid Tests & Point of Care (POC) - Recent Developments
7 Appendix
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Access Bio Inc
- Akers Biosciences Inc
- Aldatu Biosciences Inc
- Alere Inc
- Altratech Ltd
- BBB Technologies Inc
- Beijing Wantai Biological Pharmacy Enterprise Co Ltd
- Binx Health Inc
- Bio-AMD Inc
- Biocartis Group NV
- BioHelix Corp
- Calypte Biomedical Corporation
- Centre International de Reference Chantal Biya
- Cepheid
- Chembio Diagnostic Systems Inc
- CrossLife Technologies Inc
- Daktari Diagnostics, Inc.
- Diagnostics For All Inc
- Diagnostics for the Real World (Europe) Ltd
- Endeavor Sciences Inc
- Epinex Diagnostics Inc
- ERBA Molecular Ltd
- GAIA Medical Institute LLC
- genedrive plc
- Group K Diagnostics
- HeatFlow Technologies Inc
- Imperial College London
- Jinvator Bio Med GmbH
- Johns Hopkins University
- Labsystems Diagnostics Oy
- Micronics Inc
- Molbio Diagnostics Pvt Ltd
- Nanobiosym Inc
- NeuMoDx Molecular Inc
- Newmark Diagnostics LLC
- Northwestern University
- Orangelife
- Osel Inc
- QuantuMDx Group Ltd
- Quidel Corp
- Radisens Diagnostics Ltd
- Rheonix Inc
- Roche Diagnostics International Ltd
- Sedia Biosciences Corp
- TheoremDx Inc
- Trinity Biotech Plc
- University of Washington
- UrSure Inc
- Wave 80 Biosciences Inc
- Yaathum Biotech Pvt Ltd